Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an upd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40287 IKENA ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) | Delawar ...

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast Link The web ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY, INC. (Exact name of Registrant as specified in its charter) Delaware 81-1697316 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40287 IKENA ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaw ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40287 IKENA ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (857) 273-8343 Securities registered pursuant to S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40287 IKENA ONCOLOGY, INC. (Exact name of Registrant as specified in its charter) | Delaware | 81-1697316 | | --- | --- | | (State or ...

Financial Performance - The company has incurred net losses of $54.7 million and $36.9 million for the nine months ended September 30, 2022 and 2021, respectively, with an accumulated deficit of $200.1 million as of September 30, 2022[83]. - Net loss for the three months ended September 30, 2022, was $17.3 million, a 19% increase from the net loss of $14.5 million in the same period of 2021[105]. - Net cash used in operating activities was $56.5 million for the nine months ended September 30, 2022, compared to $46.9 million in the same period of 2021[111]. Revenue and Funding - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[92]. - The company completed an IPO on March 30, 2021, raising approximately $131.3 million in net proceeds from the sale of 8,984,375 shares at a public offering price of $16.00 per share[81]. - The company anticipates needing substantial additional funding to support ongoing operations and research and development efforts[116]. - The company filed a shelf registration statement covering the offering of up to $300.0 million in common stock, preferred stock, debt securities, and other units, with no sales made under the ATM Program as of the current date[119]. Research and Development - The company is developing IK-930, an oral small molecule inhibitor targeting the Hippo pathway, with initial clinical data expected in 2023[77]. - The company is evaluating IK-175 in a Phase 1a/1b clinical trial for advanced solid tumors, with initial data expected to be shared at the 2022 Society for Immunotherapy of Cancer Annual Meeting[79]. - The company plans to assess IK-930 in combination with other targeted therapies, including osimertinib and MEK inhibitors, across several indications[77]. - The company has paused further development of the IK-412 program due to manufacturing delays caused by COVID-19[91]. - The company expects significant increases in expenses related to ongoing research and development and potential commercialization of product candidates[115]. Operating Expenses - Total operating expenses rose by 33% to $24.3 million for the three months ended September 30, 2022, compared to $18.3 million in the same period of 2021[105]. - Research and development expenses increased by $5.5 million (41%) for the three months ended September 30, 2022, primarily due to increased personnel and overhead costs[107]. - General and administrative expenses increased by $0.5 million (11%) for the three months ended September 30, 2022, attributed to higher compensation and insurance expenses[109]. - The company anticipates significant increases in operating expenses as it continues to invest in research and development[84]. Cash and Investments - The company has cash, cash equivalents, and marketable securities of $174.4 million as of September 30, 2022, which is expected to fund operations through mid-2024[87]. - Cash, cash equivalents, and marketable securities totaled $174.4 million as of September 30, 2022[110]. - The increase in cash used in investing activities was primarily due to purchases of marketable securities totaling $189.9 million[113]. - The company invests cash in various financial instruments, primarily U.S. government securities and investment-grade corporate bonds, with no significant exposure to interest rate risk[129]. Lease and Contingent Payments - The company has a non-cancelable operating lease agreement with expected payments totaling $1.8 million in 2022, increasing annually through 2026[120]. - The company may incur contingent payments upon achieving clinical, regulatory, and commercial milestones, but the amounts are not fixed or determinable at this time[123]. Accounting and Market Risk - The company has not experienced material changes in critical accounting policies during the nine months ended September 30, 2022[124]. - The company is not currently exposed to significant market risk related to foreign currency exchange rates and does not believe inflation materially affected its financial condition during the nine months ended September 30, 2022[130].

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40287 IKENA ONCOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...